Human Recombinant Insulin Market

Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver.Recombinant human insulin has a significant advantage over insulin from other animal sources. Patients can better absorb human insulin.It is also easier to manage allergies related to insulin intake.
Human Recombinant Insulin Market contains market size and forecasts of Human Recombinant Insulin in global, including the following market information:
Global Human Recombinant Insulin Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Human Recombinant Insulin Market Sales, 2017-2022, 2023-2028, (K Litre)
Global top five Human Recombinant Insulin companies in 2021 (%)
The global Human Recombinant Insulin market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Rapid-Acting Human Insulin Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Human Recombinant Insulin include Novo Nordisk, Eli Lilly and Company, Sanofi, Julphar Gulf Pharmaceutical Industries, Bioton, Gan & Lee Pharmaceuticals, Zhuhai United Laboratories, Biocon and Wanbang Biopharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Human Recombinant Insulin manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Human Recombinant Insulin Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Litre)
Global Human Recombinant Insulin Market Segment Percentages, by Type, 2021 (%)
Rapid-Acting Human Insulin
Regular (Short Acting) Insulin
NPH (Intermediate Acting) Insulin
Long-Acting Human Insulin
Premixed Human Insulins Insulin
Global Human Recombinant Insulin Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Litre)
Global Human Recombinant Insulin Market Segment Percentages, by Application, 2021 (%)
Hospital
Retail Pharmacy
Online Pharmacies
Other
Global Human Recombinant Insulin Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Litre)
Global Human Recombinant Insulin Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Human Recombinant Insulin revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Human Recombinant Insulin revenues share in global market, 2021 (%)
Key companies Human Recombinant Insulin sales in global market, 2017-2022 (Estimated), (K Litre)
Key companies Human Recombinant Insulin sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novo Nordisk
Eli Lilly and Company
Sanofi
Julphar Gulf Pharmaceutical Industries
Bioton
Gan & Lee Pharmaceuticals
Zhuhai United Laboratories
Biocon
Wanbang Biopharmaceuticals
Dongbao Enterprise Group
PeproTech